ライフサイエンスコーパス: histamine release

1 to have antipruritic activity by suppressing histamine release.

2 ication, which may account for their role in histamine release.

3 s used as a priming agent for human basophil histamine release.

4 TCTP, which corresponded to the magnitude of histamine release.

5 antihistamine blockade, and measured dermal histamine release.

6 nd basophil responses to BmAg as measured by histamine release.

7 E of greater than 500:1 to suppress basophil histamine release.

8 ion as measured by D. pteronyssinus-specific histamine release.

9 in Fc epsilon RI-induced Ca(2+) response and histamine release.

10 effect on CD63 and CD203c externalization or histamine release.

11 cortex synaptosomes for inhibition of [(3)H]histamine release.

12 had a significant effect on antigen-induced histamine release.

13 on by means of the suppression of endogenous histamine release.

14 iled to reconstitute Fc epsilon RI-initiated histamine release.

15 k for downstream signaling events leading to histamine release.

16 on basophils and a decrease in Ag-triggered histamine release.

17 ing did not enhance FcvarepsilonRI-dependent histamine release.

18 protein expression and FcepsilonRI-mediated histamine release.

19 es and downstream propagation of signals for histamine release.

20 while inhibiting LTC4 generation as well as histamine release.

21 Four treated patients had no symptoms of histamine release.

22 ise [Ca(2+)](i) in ECL cells, and stimulated histamine release.

23 TBC-1269, was associated with a reduction in histamine release.

24 lipase C-gamma and a dramatic enhancement of histamine release.

25 induced prolonged airway hyperreactivity and histamine release.

26 ion (IC50 = approximately 2 microM), but not histamine release.

27 with resting T cells resulted in significant histamine release.

28 on of PMA-induced, but not anti-IgE-induced, histamine release.

29 and mitogen-activated protein kinase, and no histamine release.

30 ed to determine whether they were capable of histamine release.

31 he only cytokine shown to induce substantial histamine release.

32 , an increase in intracellular free Ca2+ and histamine release.

33 trin-driven enterochromaffin-like (ECL) cell histamine release.

34 effects of zolpidem do not depend on reduced histamine release.

35 ases showed >/=10% allergen-specific maximum histamine release.

36 tion of TRPM7 in mast cell degranulation and histamine release.

37 e levels with ten persons showing negligible histamine release.

38 by temperature, mast cell degranulation and histamine release.

39 loss occurred despite the presence of little histamine release.

40 EC did not significantly reduce constitutive histamine release.

41 nd IgE-dependent human lung mast cell (HLMC) histamine release.

42 Cross-linking I/I/gamma elicited histamine release, [14C]arachidonic acid metabolites, ty

43 to significant degranulation as evidenced by histamine release (24.5 +/- 4.4%): and up-regulation of

44 Since MIP-1alpha has potent inflammatory and histamine-releasing activities, its production by basoph

45 ity while retaining high potency and lack of histamine releasing activity.

46 ted the effects on mast cell binding and the histamine-releasing activity of l-alanine substitutions

47 Histamine release after ALA-PDT mirrored the urticarial

48 overexpression of UCP2 in LAD2 cells reduced histamine release after both allergic and nonallergic tr

49 ed as a novel functional readout of basophil histamine release after immunotherapy.

50 ne, and is associated with increased central histamine release and alterations in histamine H(3) rece

51 ed by their immunoglobulin E (IgE)-dependent histamine release and by their characteristic proliferat

52 cell that inhibits gastrin-induced ECL cell histamine release and Ca2+ entry by activation of a Gi o

53 The inhibitory actions of galanin on histamine release and Ca2+ influx could be reduced by a

54 Inhibition of ECL cell histamine release and calcium signaling is produced by s

55 Y and related peptides on gastrin-stimulated histamine release and calcium signaling was eliminated b

56 measurement of basophil CD63 expression and histamine release and casein-specific CD4(+) regulatory

57 blast-mast cell interaction for induction of histamine release and chemokine production and the speci

58 L-902,688, TCS251) agonists on IgE-dependent histamine release and cyclic-AMP generation in mast cell

59 cell contact plays a role in exacerbation of histamine release and eotaxin production.

60 ells were analyzed in short-term culture for histamine release and for changes in intracellular calci

61 tudy examined the possible role of increased histamine release and granulocyte activity in the vascul

62 tely 2 microM), with only a modest effect on histamine release and IL-4 production at higher concentr

63 actor (HrHRF) is known to directly stimulate histamine release and IL-4 secretion from basophils of s

64 the pathway for LTC4 generation, but not for histamine release and interleukin-4 production.

65 lls, aggregation of Fc epsilon RI induced no histamine release and no detectable increase in total ce

66 Inhibition of histamine release and of calcium entry by PYY and [Pro34

67 ebrin(-/-) mice exhibit reduced IgE-mediated histamine release and passive systemic anaphylaxis, and

68 Aggregation of Fc gamma RI resulted in histamine release and PGD(2) and LTC(4) generation.

69 nduced by rHRF significantly correlated with histamine release and the amount of protein generated, a

70 These models differentially relied on histamine release and the contribution of mast cells, ba

71 An increase in histamine release and the number of granulocytes was obs

72 tyrosine phosphorylation of Syk and minimal histamine release and weak phosphorylation of activation

73 skin induced by PAF are not associated with histamine release and, therefore, appear to be independe

74 ts are mediated predominantly by C5a-induced histamine release, and 3) that C3a does not contribute s

75 Hemodynamic measurements, symptoms of histamine release, and plasma histamine levels were obta

76 OVA (10 microg ml(-1)) caused histamine release (approximately total tissue content),

77 F-heparin and LMWH inhibited antigen-induced histamine release as measured in BALF by 81% and 75%, re

78 null mice have reduced allergen/IgE-induced histamine release, as well as early airway hyperresponsi

79 at comparing basophil activation test (BAT), histamine release assay (HR), and passive sensitization

80 elease assay (HR), and passive sensitization histamine release assay (passive HR) in the diagnosis of

81 25% of CU patients have a positive basophil histamine release assay and show autoreactivity (a posit

82 Results with the basophil histamine release assay corroborated these findings (P <

83 ld reduction in allergenicity when tested by histamine release assay with basophils of yellow jacket-

84 er gene assay (IC50 and pA2) and an in vitro histamine release assay.

85 d FcepsilonRIalpha by basophil and mast cell histamine release assays and by basophil activation assa

86 umvent potential soluble inhibitors, such as histamine released at sites of inflammation, and allow t

87 in prick test titration (SPTT), and basophil histamine release (BHR) to peanut.

88 Histamine release, bradykinin generation, and cytokine r

89 stamine release, together caused significant histamine release but no apparent PKC translocation.

90 t from IL-3, which also primes basophils for histamine release, but does show phosphorylation of thes

91 Immunotherapy inhibits basophil histamine release, but the assay is cumbersome, and no o

92 1 up to 70% and suppressed allergen-mediated histamine release by 10-fold.

93 lanin inhibited basal and gastrin-stimulated histamine release by approximately 60% with a median eff

94 f mast cell degranulation potently inhibited histamine release by mast cells and inhibited adipocyte

95 We found that peptide 5 did not inhibit histamine release by peptide 1.

96 on of dura with estradiol slightly augmented histamine release by SP, an effect possibly mediated thr

97 Until recently, it was mainly attributed to histamine released by mast cells activated by allergen c

98 These results demonstrate that histamine released by MCs reduces diabetic host resistan

99 us and allergen-induced basophil reactivity (histamine release, CD63 expression, and IL-4 production)

100 la(17) (6), and Ala(21) (7) showed a loss of histamine release compared to the parent MCD peptide 1.

101 This analogue 5 showed a 130-fold loss of histamine release compared to the parent peptide 1.

102 CM-specific IgE and IgG(4) levels, basophil histamine release, constitutive CD63 expression, CD203c

103 mechanism by which mast cell activation and histamine release contribute to skin barrier defects in

104 ng mast cell-fibroblast coculture, increased histamine release could be attenuated either by separati

105 oclonal antibody significantly inhibited net histamine release, cysLT production, and IL-4 generation

106 GE2 1) significantly inhibited IgE-mediated histamine release, cytokine production, and Ca(2+) mobil

107 There is evidence that histamine released during inflammation plays a role in b

108 ations that inhibit proton current inhibited histamine release elicited by PMA or anti-IgE.

109 findings suggest that the diurnal rhythm of histamine release entrains striatal function which, duri

110 ive correlation between histamine release to histamine releasing factor/translationally controlled tu

111 I, Ando et al. provide a causal link between histamine-releasing factor (HRF) interactions with IgE a

112 protein (TCTP) is a homolog of the mammalian histamine-releasing factor (HRF), which causes histamine

113 GAP that lacks a secreted factor related to histamine-releasing factor (HRF).

114 Histamine-releasing factor (HRF; also known as translati

115 Human recombinant histamine-releasing factor (HrHRF) is known to directly

116 Human recombinant histamine-releasing factor (HrHRF) preincubation enhance

117 A novel recombinant histamine-releasing factor (rHFR), which stimulates secr

118 Human recombinant histamine-releasing factor has also recently been shown

119 that HrHRF, in addition to functioning as a histamine-releasing factor, can differentially modulate

120 unction, a novel molecule, the IgE-dependent histamine-releasing factor, was cloned.

121 d by anti-IgE Ab or by the human recombinant histamine-releasing factor.

122 analogues showed a 5- to 6-fold decrease in histamine release for analogues 6, 7, and 4 and a 10-fol

123 is a calcium-binding protein that can cause histamine release from basophil/mast cells and induce eo

124 ombinant malarial TCTP, like HRF, stimulated histamine release from basophils and IL-8 secretion from

125 ckers were found to inhibit anti-IgE-induced histamine release from basophils in nonallergic subjects

126 for monocytes and eosinophils and stimulated histamine release from basophils.

127 ent inhibition of Fel d1-driven IgE-mediated histamine release from cat-allergic donors' basophils an

128 oms and cause non-immunoglobulin E-dependent histamine release from circulating basophils.

129 The peptides inhibit histamine release from cultured cells and are extremely

130 AF-induced wheal development is secondary to histamine release from dermal mast cells.

131 NGASP stimulates histamine release from ECL cells, but the release is not

132 In vivo, gastric acid secretion and in vitro histamine release from enterochromaffin-like (ECL) cells

133 gastritis, inhibits both parietal cells and histamine release from enterochromaffin-like cells.

134 c rhinitis proceeded in two distinct stages: histamine release from FcepsilonRI-activated mast cells,

135 nt inhibition of antigen-driven IgE-mediated histamine release from fresh human basophils sensitized

136 5a-induced thromboxane (TXB2) generation and histamine release from HMC-1 cells and whole-blood basop

137 stamine-releasing factor (HRF), which causes histamine release from human basophils and IL-8 secretio

138 preparations was also tested in an assay of histamine release from human basophils in whole blood.

139 The purified protein elicits histamine release from human basophils passively sensiti

140 Desensitization of IgE-mediated histamine release from human lung mast cells was explore

141 E2 ) has been shown to inhibit IgE-dependent histamine release from human lung mast cells.

142 f peripheral blood eosinophils and to induce histamine release from IL-3-primed peripheral blood baso

143 study was to determine whether PYY inhibits histamine release from isolated enterochromaffin-like (E

144 in vitro method to analyze the properties of histamine release from LAD2 cells and characterize the s

145 loped a sensitive and rapid method to detect histamine release from LAD2 cells using liquid chromatog

146 f the gadolinium-based MRI contrast media on histamine release from mast cells and to compare the act

147 IgE/DNP-human serum albumin-stimulated histamine release from mast cells was inhibited by appro

148 sts and EP4 agonists inhibited IgE-dependent histamine release from mast cells.

149 vated by PMA or immobilized anti-CD3 mAb, on histamine release from murine bone marrow-derived cultur

150 or histamine antagonism in vitro (Ki for [3H]histamine release from rat cerebral cortex synaptosomes)

151 The ability of the lectins to induce histamine release from rat peritoneal mast cells is show

152 part by inhibition of calcium signaling and histamine release from the ECL cells due to activation o

153 of the untreated BP patients were tested for histamine release from their basophils in response to NC

154 7 h after toxin treatment but did not induce histamine release from these cells.

155 tivation was presented as mean percentage of histamine released from cells after incubation.

156 Histamine released from retinopetal axons in the mouse r

157 A major action of histamine released from retinopetal axons under dark-ada

158 Histamine, released from activated mast cells, causes br

159 Histamine, released from ECL cells, stimulates the parie

160 Histamine, released from enterochromaffin-like cells sti

161 Histamine, released from fundic enterochromaffinlike cel

162 Constitutive and FcepsilonRI-dependent HLMC histamine release, HASMC contraction, and beta2-AR phosp

163 e CSU disease, reduced IgE-mediated basophil histamine release (HR) and basopenia are observed.

164 within three months prior to OFC to measure histamine release (HR) and specific IgE antibody titers.

165 in a paradoxical increase in their basophil histamine release (HR) response ex vivo to cross-linking

166 specific, and HDM-allergen-specific basophil histamine release (HR), plus helminth- and HDM-specific

167 g D1 and D2 and lipoxin A(4) attenuated HLMC histamine release in a dose-dependent fashion but were n

168 lone was able to drive substantial levels of histamine release in about a third of all preparations s

169 in biological fluids and inhibited cellular histamine release in an in vitro bioassay of IgE activit

170 ion of A(3) receptors could induce mast cell histamine release in association with increases in intra

171 and CNX-774) on IgE-dependent activation and histamine release in blood basophils obtained from aller

172 heparin [ULMWH]) on antigen-induced AHR and histamine release in bronchoalveolar lavage fluid (BALF)

173 n was found to downregulate anti-IgE-induced histamine release in CD30(+) MCs.

174 whether galanin inhibits Ca2+ signaling and histamine release in enterochromaffin-like (ECL) cells.

175 onfirmed by demonstrating that IgE-dependent histamine release in ex vivo blood basophils is largely

176 drugs are potent inhibitors of IgE-dependent histamine release in human basophils.

177 riction in sheep, inhibits anti-IgE mediated histamine release in isolated mast cells, and prevents t

178 an essential role in Fc epsilon RI-mediated histamine release in mast cells by regulating the phosph

179 CIU patients with basophil histamine release in response to polyclonal goat anti-hu

180 wed a >/=10% concentration-dependent maximum histamine release in response to the anti-human IgE stim

181 hibitor with an expected IC(50), and induced histamine release in strict proportion to release induce

182 Cytokine-specific stimulation of histamine release in the airway-derived and bone marrow-

183 However, receptor-induced histamine release in the cells expressing either wild-ty

184 occurrence of satiety onset while increasing histamine release in the CNS with an H3 receptor antagon

185 OEA augmented histamine release in the cortex of fasted mice within a

186 i in the scotopic range during the day, when histamine release in the retina is expected to be at its

187 lices to examine the effects of photo-evoked histamine release in the ventrolateral TMN and VLPO.

188 cient W/W(v) animals is able to fully rescue histamine release in the W/W(v) mice.

189 Quantities of histamine released in spontaneous HR and egg white (EW)-

190 Accordingly, histamine release, in an in vivo passive systemic anaphy

191 However, IgE-dependent histamine release increased in washed cell preparations

192 AHG2 inhibited histamine release induced by whole peanut extract (WPE)

193 Secretagogue-induced histamine release, inflammation and airway contraction a

194 nstriction, allergic cutaneous reaction, and histamine release into bronchoalveolar lavage fluid (BAL

195 t changes in airway resistance and attenuate histamine release into the bronchoalveolar lavage, sugge

196 factor determining quantal size of 5-HT and histamine release, intragranular association with the he

197 nic responses in the surrounding tissue, and histamine release is known to promote rapid diapedesis o

198 The level of histamine release is tightly connected to behavioral sta

199 analyzed by video imaging of [Ca(2+)](i) and histamine release; its effects on gastric glands were ex

200 it prostaglandin E2-stimulated secretion via histamine release, likely from mast cells, and actions o

201 multaneous phenotyping and quantification of histamine release might add to our knowledge about the b

202 nhibited neurons, resulting in excitation of histamine-releasing neurons in the TMN through disinhibi

203 degranulation of mast cells, accompanied by histamine release, occurs adjacent to short-term i.p. im

204 r mast cell proteases-1, -4, -5, and -6, and histamine release on ligation of surface IgE or stimulat

205 with SM did not show increased IgE-dependent histamine release or CD63 upregulation.

206 OVA failed to elicit histamine release or contractile responses in trachea is

207 generation by phosphorylating cPLA2, but not histamine release or IL-4 production, in human basophils

208 o detectable effect on Fc epsilon RI-induced histamine release or on the phosphorylation of total cel

209 The lipopeptide had no effect on basophil histamine release or on the proliferation of B cells and

210 oduction by the primed hMCs occurred without histamine release or PGD(2) generation and was inhibited

211 Indeed, the kinetics of histamine release paralleled the kinetics of the formati

212 Following FMLP stimulation, histamine release preceded phosphorylation of ERKs, wher

213 We found that degranulation and histamine release proceeded independently of TRPM7 chann

214 Codeine caused a significant but variable histamine release, ranging from 29 to 282 ng/ml.

215 the clinical significance of the spontaneous histamine release ratio (SHR/T) and low responders in th

216 y means of ImmunoCAP inhibition and basophil histamine release, respectively.

217 lution, returned to 80% of baseline, whereas histamine release responses returned to baseline.

218 io, cell-surface FcepsilonRI expression, and histamine release responses to anti-IgE antibody or pean

219 polyclonal anti-IgE and Ag-induced basophil histamine release responses.

220 3)- and Panx1 HC-dependent MC dye uptake and histamine release, responses that were only Cx43 HC depe

221 ng/mL IL-3, the concentration-dependence of histamine release shifted to 100-fold lower concentratio

222 In inflammatory skin diseases with enhanced histamine release, such as psoriasis and atopic dermatit

223 and low responders in the automated basophil histamine release test (Allerport HRT).

224 ific IgE (Immunocap(R) ; Phadia AB, Sweden), histamine release test (HR) (RefLab ApS, Denmark), skin

225 ter of specific IgE antibody and/or basophil histamine release test against Glupearl 19S(R) revealed

226 ly identified a negative correlation between histamine release to histamine releasing factor/translat

227 alone caused no PKC translocation and little histamine release, together caused significant histamine

228 tion of TRPM7 on mast cell degranulation and histamine release using wild-type (TRPM7(+/+) ), TRPM7(+

229 ups, whereas CM-specific IgE and spontaneous histamine release values decreased in only the OIT group

230 Histamine release was also enhanced by the stable expres

231 pyridone 16 by dose-dependent inhibition of histamine release was demonstrated in a rodent pharmacod

232 hat analogue 5 inhibits peptide 1-stimulated histamine release was examined.

233 Constitutive HLMC histamine release was increased in HLMC-HASMC coculture

234 combined with SCF, a synergistic increase in histamine release was induced in upper airway, but not b

235 Gastrin-stimulated histamine release was inhibited with a 50% inhibiting co

236 Suppression of histamine release was likely not observed in either of t

237 effect of rfhSP-D on basophil activation and histamine release was measured by flow cytometry.

238 BP180-stimulated histamine release was measured from basophils of untreat

239 activation, the marked shift in the EC50 for histamine release was not accompanied by similar shifts

240 On the other hand, concentration-dependent histamine release was not seen in the"NON"responders, su

241 Antigen-specific histamine release was observed only in those patients wi

242 were incubated with participants' serum and histamine release was quantified as HR.

243 BP180-stimulated histamine release was significantly higher in basophils

244 Within the hippocampus, histamine release was significantly increased on day 9,

245 In fact, FcepsilonRI-mediated MC histamine release was synergistically increased by metop

246 ress the hypothesis that mycoplasma provokes histamine release, we exposed mice to Mycoplasma pulmoni

247 eactions are triggered by mast cell-mediated histamine release, we investigated the function of TRPM7

248 ex binding to B cells (IgE-FAB) and basophil histamine release were also determined.

249 inhibitory activity for IgE-FAB and basophil histamine release were also significantly greater in all

250 Both constitutive and IgE-dependent HLMC histamine release were attenuated by BEAS-2B, primary AE

251 Drug effects on allergen-induced histamine release were dose dependent, with IC50 values

252 Allergen-induced basophil responsiveness and histamine release were inhibited in the presence of rfhS

253 f PYY and somatostatin on gastrin-stimulated histamine release were observed.

254 Furthermore, those donors who have direct histamine release when exposed to HRF/TCTP (HRF/TCTP res

255 onists did not affect the PGE2 inhibition of histamine release, whereas EP2 -selective antagonists ca

256 BMMCs from Ucp2(-/-) mice exhibited greater histamine release, whereas overexpression of UCP2 in LAD

257 ) stimulation revealed strong suppression of histamine release, whereas removal of extracellular Mg(2

258 TE dose-dependently stimulated histamine release, which was not blocked by a cholecysto